Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
8 evidence topics · 9 sources
Typical CIDP and CIDP variants
“Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A diverse and complex interplay of different immunopathological mechanisms, involving cellular, humoral and complement pathways, culminates in a highly variable pattern of peripheral nerve damage in different clinical variants of CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody-mediated nodopathies: response to standard therapy
“A breakthrough in CIDP antibody autoimmunity has been the remarkable observation that a subset of patients who do not respond to IVIg or plasmapheresis have IgG4 antibodies to nodal/paranodal antigens directed against neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammatory therapies, especially with IVIg, immunosuppressants, and plasmapheresis, are ineffective or not sufficiently effective in inducing long-term remissions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, data from large series of patients with MuSK myasthenia, CIDP with nodal/paranodal antibodies, and anti-LGI1 and CASPR2-associated syndromes indicate that B cell depletion therapy with rituximab exerts long-lasting clinical remissions by targeting memory B cells and IgG4-producing CD20-positive short-lived plasma cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody subclass and expected relevance of complement inhibition
“It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, complement involvement in certain subgroups of CIDP patients, including those with non-complement fixing antibodies, is not yet certain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response by disease course to plasma exchange
“Fifteen patients completed the trial and of those, 12 patients (80%) improved substantially with PE; i.e. five out of seven patients with chronic progressive course and seven out of eight patients with relapsing CIDP improved.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The PE non-responders improved with prednisone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-response and alternative diagnoses
“Alternative diagnosis was made in 7 out of 12 (58%) who did not respond to any therapy and in none of the treatment-responsive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In treatment-nonresponsive patients, the diagnosis CIDP should be reconsidered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote